REINFORCING THE PLANT’S NATURAL ABILITY TO WITHSTAND STRESSES, RESULTING IN A HEALTHIER PLANT DELIVERING MORE MARKETABLE CROPįormulation registered, tested and approved by research and farmers:īio-Forge® is a patented formulation of N,N’ - diformyl urea, classified as an antioxidant, and shown to significantly improve growth in a variety of agricultural crops by working on the genetic level. For more information visit that aims to promote the correct hormone balance, reduce stress and enhance development and production efficiency of plants. With 100+ employed clinicians and more than 700 teammates in over 60 clinic locations and growing, TOI is changing oncology for the better. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.įounded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Together, these industry leaders are poised to reshape the future of oncology and bring new hope to patients and their families. The alliance between Massive Bio and TOI represents a paradigm shift in cancer care, combining the power of advanced AI technology, personalized therapy, and an extended network of research collaborations. The integration of AI-driven chatbots with clinical decision-support tools will revolutionize the way researchers access and analyze oncology data, enabling more efficient and impactful research initiatives, and will bolster this newly forged alliance to the betterment of all cancer patients." Arturo Loaiza-Bonilla, renowned oncologist and a key figure in the development of the chatbot technology, stated, "We are proud to be part of this innovative partnership between Massive Bio and TOI. Our combined expertise will open new doors for patients, connecting them to potentially life-saving treatments and groundbreaking clinical trials."įurthermore, this collaboration will expand the scope of cancer research through Massive Bio's recent ChatGPT-powered chatbots for oncology research release during ASCO 2023. "This partnership will not only revolutionize cancer care but will also empower patients with access to the most advanced precision medicine available. "We are incredibly excited about joining forces with The Oncology Institute," said Selin Kurnaz, Ph.D., CEO of Massive Bio. By leveraging AI-driven precision medicine, we are confident that this partnership will accelerate breakthroughs in cancer research and deliver life-changing treatment options to our patients." ![]() By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services.Ĭristina Green, Vice President of Clinical Research, shared her enthusiasm for this partnership, stating, "This collaboration with Massive Bio complements our ability to connect patients with advanced cancer therapies and cutting-edge clinical trials. Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. ![]() This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network. NEW YORK-( BUSINESS WIRE)- Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |